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Major depressive disorder (MDD) is a substantial burden to patients,
families, and society, but many patients cannot be treated adequately.
Rodent experiments suggest that the neuropeptide galanin (GAL) and
its three G protein-coupled receptors, GAL1–3, are involved in mood
regulation. To explore the translational potential of these results, we
assessed the transcript levels (by quantitative PCR), DNA methyl-
ation status (by bisulfite pyrosequencing), and GAL peptide by RIA of
the GAL system in postmortem brains fromdepressed personswho had
committed suicide and controls. Transcripts for all four members were
detected and showed marked regional variations, GAL and galanin re-
ceptor 1 (GALR1) being most abundant. Striking increases in GAL and
GALR3mRNA levels, especially in the noradrenergic locus coeruleus and
the dorsal raphe nucleus, in parallel with decreased DNA methylation,
were found in both male and female suicide subjects as compared with
controls. In contrast, GAL and GALR3 transcript levels were decreased,
GALR1 was increased, and DNA methylation was increased in the dor-
solateral prefrontal cortex of male suicide subjects, however, there
were no changes in the anterior cingulate cortex. Thus, GAL and its
receptorGALR3 are differentially methylated and expressed in brains of
MDD subjects in a region- and sex-specific manner. Such an epigenetic
modification in GALR3, a hyperpolarizing receptor, might contribute to
the dysregulation of noradrenergic and serotonergic neurons impli-
cated in the pathogenesis of MDD. Thus, one may speculate that
a GAL3 antagonist could have antidepressant properties by disinhibiting
the firing of these neurons, resulting in increased release of noradren-
aline and serotonin in forebrain areas involved in mood regulation.
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Major depressive disorder (MDD) is a serious mental illnessaffecting up to 20% of the population at some point during
their lives, women more frequently than men, and representing a
major burden to patients, their families, and society (1, 2). MDD is
thought to arise from the interaction of genetic and environmental
factors, with stressful life events representing an important predis-
posing factor (3–5). Growing evidence suggests that epigenetic
mechanisms mediate such interactions, namely through altered DNA
methylation, thus leading to stable changes in brain function that may
underlie psychopathology (6, 7).
Pharmacological management of depression currently involves
drugs that often target the monoamine transporters, which include
selective reuptake inhibitors for serotonin (5-hydroxytryptamine,
5-HT) (SSRIs), noradrenaline (NA) inhibitors (NRIs), or a com-
bination of both (SNRIs) (8–10), as well as a number of other
medications (11). However, the therapeutic efficacy of these anti-
depressants is hampered by a slow onset of action, a limited re-
sponse rate, and considerable side effects (12, 13). These issues have
led to intensive search for novel therapeutic approaches for MDD
(14), including targeting receptors for neuropeptides (15–19), the
most diverse family of brain messenger molecules (20).
In this context, the 29/30 amino acid neuropeptide galanin
(GAL) (21), which is widely distributed in the rat (22–25) and
human (26) brain, may be of special interest. In particular, it co-
exists with NA in the locus coeruleus in both rat (27–29) and
human (26, 30–32) and in rat with 5-HT in the dorsal raphe nu-
cleus (28, 33, 34).
Significance
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nificant changes in the transcript and DNA methylation levels
of GAL and galanin receptor 3 (GALR3) in the locus coeruleus
and dorsal raphe nucleus, two regions important for mood
regulation. Our findings suggest GAL3 involvement in depressive
disorder, making it a possible drug target for this disease.
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GAL exerts its physiological actions via three subtypes of G
protein-coupled receptors, GAL1–3 (35, 36). The distribution of
these receptors has been mapped previously with ligand-binding
autoradiography in rat (37, 38), monkey, and human (39–41)
brain. More recently the receptor transcripts have been localized
with in situ hybridization in rat brain (42–44) and in some regions
of the human brain (32). It should be noted that GAL receptor
subtypes can form dimers and heterodimers, a mechanism that
can profoundly change GAL signaling (45).
Interestingly, certain differences between species exist in regions
of potential importance for mood-related disorders. For example,
galanin receptor 3 (GalR3) mRNA has a limited distribution in the
rat brain (44), where it could not even be detected in the first
publication on the cloning of this receptor (46). However, it appears
to be expressed in human noradrenergic locus coeruleus (NA-locus
coeruleus) neurons (32). In addition GAL itself has a different
profile: it is expressed in 5-HT neurons in the dorsal raphe nucleus
in the rat but not in humans, but its expression in the locus
coeruleus is conserved in the species investigated to date.
Animal studies have provided strong evidence that the GAL
system is involved in anxiety- and depression-like behavior (33, 47–
55). A recent genetic association study supports a possible role of the
GAL system in mood disorders, pointing to involvement of epige-
netic processes and a strong association with high levels of stress
(56). Moreover, there is an interaction between GAL and the
5-HT1A receptor (47), a receptor that plays an important role as
autoreceptor in depression, as shown in experimental studies (57, 58)
and in studies of suicide victims (59). In agreement with many ani-
mal experimental studies, PET imaging also has indicated a role
for postsynaptic 5-HT1A receptors in depression (60).
The aim of the present study was to identify possible changes in
the GAL system in MDD by analyzing postmortem brains from
depressed subjects who committed suicide (hereafter “DS” subjects)
and matched subjects without psychiatric symptoms (hereafter,
simply “controls”). We used quantitative PCR (qPCR) to monitor
transcript levels, bisulfite pyrosequencing to study DNA methyl-
ation (GAL and GALR1-3), and RIA to establish GAL peptide
levels. All three analyses were carried out on the same samples from
five different, relevant brain regions: dorsolateral prefrontal cortex
[Brodmann area (BA) 8/9], anterior cingulate cortex (BA 24), locus
coeruleus, dorsal raphe nucleus, and the medullary raphe nuclei.
Results
Cohort Demographics. There were no significant differences be-
tween DS subjects and their matched controls in age (DS subjects
vs. controls: 51.6 ± 15.4 vs. 57.5 ± 15.4 y, P = 0.11); postmortem
interval (PMI) (DS subjects vs. controls: 43.56 ± 24.16 vs. 49.21 ±
34.44 h, P = 0.94); brain pH (DS subjects vs. controls: 6.61 ±
0.29 vs. 6.46 ± 0.34; P = 0.13); or RNA integrity number (RIN)
(DS subjects vs. controls: 6.49 ± 1.70 vs. 6.68 ± 1.62; P < 0.49).
The details of the demographic characteristics of DS subjects and
controls for each of the regions analyzed are provided in Table 1,
and detailed information on each individual subject is provided
in Table S1.
Sample Anatomy. The five brain regions analyzed encompass a
heterogeneous collection of neurons. It is important to note that in
the samples labeled locus coeruleus and especially in those labeled
dorsal raphe and medullary raphe only a part of these neurons are
monoaminergic (SI Materials and Methods, Brain Samples).
The Effects of Medication.An inherent problem of autopsy analysis
is the effect of medication, particularly when looking at a dynamic
parameter, such as transcripts. For example, it has been reported
that an antidepressant can exert epigenetic changes (61, 62). We
have analyzed the data using ANOVA followed by Fisher’s least
significant difference post hoc test and ANCOVA by treating an-
tidepressants as a confounding factor to compare the effects in
male and female DS subjects. The samples were divided into four
groups based on the different medications, namely (i) SSRIs,
(ii) SSRI + benzodiazepines, (iii) SSRI + others (including SNRIs,
serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine-
dopamine reuptake inhibitors, tricyclic antidepressants, and
noradrenergic and specific serotonergic antidepressants; details
are given in Table S1), and (iv) none. Based on the analysis, we
conclude that in our study the various psychiatric medications
show no significant effect on the gene expression of GAL and
GalR3 in the five regions analyzed. The longer imprints of DNA
methylation would require analysis of the complete anamnesis.
Transcript Levels Vary Across Brain Regions. The overall distribution
and levels of the transcripts of the galanin system are summarized in
Table 2. Briefly, transcripts for GAL and GAL1–3 are differentially
expressed in the five brain regions, with the difference reaching
statistical significance for all the markers studied (see Tables S2 and
S3 for P values). GAL is expressed at high levels in the lower
brainstem and at three- to-fourfold lower levels in the two cortical
Table 1. Demographic characteristics of the cohort
Samples DLPFC ACC DRN LC MRN
Size 40 40 42 42 47
% male controls (n) 25 (10) 25 (10) 26.1 (11) 23.8 (10) 25.5 (12)
% male DS subjects (n) 25 (10) 25 (10) 24.1 (10) 23.8 (10) 21.2 (10)
% female controls (n) 25 (10) 25 (10) 26.1 (11) 28.5 (12) 25.5 (12)
% female subjects DS (n) 25 (10) 25 (10) 24.1 (10) 23.5 (10) 27.66 (13)
Age: mean years ± SD 60.3 ± 14.49 60.9 ± 13.8 57.2 ± 16.8 60.9 ± 15.6 58.1 ± 15.62
PMI: mean hours ± SD 44.36 ± 28.91 46.28 ± 28.8 45.58 ± 28.33 47.67 ± 30.58 43.69 ± 26.02
pH value: mean ± SD 6.52 ± 0.35 6.55 ± 0.33 6.47 ± 0.34 6.55 ± 0.36 6.56 ± 0.35
RIN value: mean ± SD 6.99 ± 1.81 6.58 ± 0.27 6.49 ± 1.89 6.62 ± 1.35 6.24 ± 1.02
ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DRN, dorsal raphe nucleus; LC, locus
coeruleus; MRN, medullary raphe nucleus; PMI, postmortem interval; RIN, RNA integrity number.
Table 2. Raw cycle threshold (Ct) values ± SEM for samples
from the regions analyzed in male and female controls and
DS subjects
Region GAL GalR1 GalR2 GalR3
DLPFC 27.1 ± 0.2 25.7 ± 0.2 31.4 ± 0.2 33.2 ± 0.1
ACC 27.5 ± 0.1 28.6 ± 0.1 31.6 ± 0.2 33.5 ± 0.2
DRN 26.2 ± 0.4 27 ± 0.4 29.3 ± 0.2 31.5 ± 0.4
LC 24.6 ± 0.5 26.4 ± 0.6 32.3 ± 0.1 31.4 ± 0.6
MRN 25.2 ± 0.4 26.9 ± 0.4 34.6 ± 0.2 31.9 ± 0.4
ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex;
DRN, dorsal raphe nucleus; LC, locus coeruleus; MRN, medullary raphe
nucleus.
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regions. The most prominent receptor transcript overall is GALR1,
with up to eightfold differences in regional expression (dorsolateral
prefrontal cortex > anterior cingulate cortex). The GALR2 mRNA
level is high in the dorsal raphe nucleus and low in medullary raphe
nuclei. GALR3 mRNA follows the pattern of GAL with high levels
in the lower brainstem and low levels in cortex.
Expression of GAL and Its Receptors Is Altered in the Brains of DS
Subjects. In the dorsolateral prefrontal cortex, GAL mRNA levels
were significantly decreased in male DS subjects compared with
controls (P < 0.01) (Fig. 1A) and were significantly increased in fe-
male DS subjects (P < 0.05) (Fig. 1E), a distinct sex difference.
GALR1 mRNA levels were significantly increased in both male and
female DS subjects (P < 0.05) (Fig. S1 A and C). GALR3 mRNA
levels were significantly decreased in male (P < 0.01) (Fig. 2A) but
not in female (Fig. 2E) DS subjects. However, there were no sig-
nificant changes in GALR2 mRNA levels in either sex (Fig. S1 E
and G). In the anterior cingulate cortex, no significant changes in
GAL or its receptors were found (Fig. S2).
In the dorsal raphe nucleus and locus coeruleus, GAL mRNA
levels were significantly increased in both male (P < 0.01) (Figs. 3A
and 4A) and female (P < 0.01) (Figs. 3E and 4E) DS subjects. In-
terestingly, higher levels of tryptophan hydroxylase-2 (TPH2) mRNA
and immunoreactive neurons have previously been shown in the
dorsal raphe nucleus of suicides relative to normal controls
(63, 64). GALR1 mRNA levels were significantly increased only
in the dorsal raphe nucleus of male DS subjects (P < 0.05, Fig. S3
A and C) but were not increased in the locus coeruleus of these
subjects (Fig. S4 A and C). The expression levels of GALR3 were
significantly increased in both the dorsal raphe nucleus (Fig. 5 A
and E) and locus coeruleus (Fig. 6 A and E) in both sexes, more
robustly in females (female vs. males: P < 0.01 vs. P < 0.05). No
significant changes were found in GALR2 mRNA levels in these
two regions (Figs. S3 E and G and S4 E and G).
In the medullary raphe nuclei,GALmRNA levels were significantly
increased in both male and female DS subjects (P < 0.05) (Fig. S5 A
and C). In male DS subjects, the GALR1 expression levels were sig-
nificantly increased (P < 0.05) (Fig. S5E), whereas GALR2 mRNA
levels were significantly decreased (P < 0.01) (Fig. S5I). However,
there were no significant changes in female DS subjects. On the other
hand, the expression levels of GALR3 were significantly increased in
both sexes (P < 0.05) (Fig. S5 M and O). All mRNA changes are
summarized in Table 3.
The DNA Methylation Status of GAL and GALR3 Changes in the Brain
of DS Patients. In the dorsolateral prefrontal cortex, At the first
three CpG sites analyzed (CpG1–3, Fig. 1B–D), the percentage of
methylated DNA was significantly higher in male DS subjects than
in controls (P < 0.05, P < 0.01, and P < 0.01, respectively). In female
DS subjects, the methylation status was different among the CpG
sites, with a significant increase at CpG1 and a significant decrease
at CPG2 (P < 0.05) (Fig. 1 F and G, respectively), and with no
changes at CpG3 (Fig. 1H). No significant changes were found for
any of the receptors in this brain region (Fig. 2 B–H and Fig. S1) or
for any of the four markers in the anterior cingulate cortex (Fig. S2).
In the dorsal raphe nucleus, a significant decrease was seen in the
percentage of methylated DNA in the GAL promoter of male DS
subjects, but only at the CpG1 site (P < 0.05) (Fig. 3B), with no
changes in female DS subjects (Fig. 3 F–H). Interestingly, GALR3
was the only receptor that was significantly altered in the brains of DS
subjects in a sex-dependent manner. Thus, only female DS subjects
showed a significant decrease in the percentage of methylated DNA
at CpG1 and CpG2 sites (P < 0.01) (Fig. 5 F and G, respectively).
In the locus coeruleus the percentage of methylated DNA in the
GAL promoter at CpG1 and CPG2 was significantly decreased in DS
subjects (male: P < 0.01 and P < 0.05; female: P < 0.05 and P < 0.01)
(Fig. 4 B and C and F and G, respectively). There was a signif-
icant decrease in the percentage of methylated DNA at the
CpG1 site of theGALR3 gene in DS subjects of both sexes (P< 0.05)
(Fig. 6 B and F), whereas methylation at the CpG2 site was
significantly decreased only in female DS subjects (P < 0.01)
(Fig. 6G). No changes were found at the CpG3 site (Fig. 6D andH).
There were no significant changes in the methylation status of
GAL or its receptors in either the anterior cingulate cortex or the
medullary raphe nuclei (Figs. S2 and S5). All methylation changes
are summarized in Table 3. For the region including differentially
methylated CpG sites in GAL and GALR3, a number of potential
transcription factor-binding sites were identified using the JASPER
database (Fig. S6C) (65, 66).
Fig. 1. Alterations in GAL gene expression and DNA methylation in postmor-
tem dorsolateral prefrontal cortex (BA 8/9) of male and female DS subjects.
(A and E) Quantitative RT-PCR was used to examine the mRNA expression levels
of GAL in the dorsolateral prefrontal cortex of male (A) and female (E) controls
and DS subjects. The expression level of GAL was normalized to HPRT levels and
expressed relative to their respective control levels. (B–D and F–H) Bisulfite
pyrosequencing was used to quantify percentage of DNA methylation levels at
individual CpG sites of theGAL gene in male (B–D) and female (F–H) controls and
DS subjects. All data are presented as mean ± SEM; n = 10 per group. Significant
differences between DS subjects and controls are indicated: *P < 0.05, **P < 0.01.
CON, controls; DS, depressed suicide.
Fig. 2. Alterations in GALR3mRNA and DNAmethylation in the dorsolateral
prefrontal cortex (BA 8/9) of male and female DS subjects. (A and E) Gene-
expression levels of GALR3 in the dorsolateral prefrontal cortex of male (A)
and female (E) controls and DS subjects. (B–D and F–H) Percentage of DNA
methylation levels at individual CpG sites of the GALR3 gene in male (B–D)
and female (F–H) controls and DS subjects. All data are presented as mean ±
SEM; n = 10 per group. Significant differences between DS subjects and
controls are indicated: **P < 0.01. CON, controls; DS, depressed suicide.
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Increased Concentrations of GAL Protein in the Locus Coeruleus in
Female DS Subjects. The RIA monitors intracellular, vesicle-stored
GAL concentrations and not extracellular peptide, which is rapidly
degraded (67). The concentrations varied considerably among the
regions analyzed, with low and intermediate levels in the forebrain
and medullary raphe nuclei, respectively, and high and very high
levels in locus coeruleus and dorsal raphe nucleus, respectively
(Table 4). These results are reflected in the transcript levels. With
regard to differences between DS subjects and controls, significant
changes were only found in the female locus coeruleus (P = 0.025)
(Fig. S7I), where the mean concentration was 56% higher in DS
subjects than in controls (67.7 vs. 43.4 pmol/mg) (Table 4). In the
dorsolateral prefrontal cortex there was an apparent difference
between male and female controls, on the one hand, and male and
female DS subjects, on the other. However, the differences in the
mean and median concentrations of immunoreactive GAL did not
reach statistical significance (P < 0.05) using either logarithmically
transformed data in a parametric ANOVA or in a Kruskal–Wallis
nonparametric test on nontransformed data.
Discussion
The present study provides a comprehensive set of results suggesting
that the GAL system has an important role in MDD. The analysis of
postmortem brain samples from DS subjects and matched controls
reveals significant increases in transcription levels for GAL and
GALR3 with parallel decreases in DNA methylation in the locus
coeruleus in DS subjects of both sexes. A similar profile was seen in
the dorsal raphe nucleus samples, although the methylation changes
were found mainly for the female GALR3 transcript. In contrast, in
the forebrain GAL mRNA levels were decreased in the male but
were increased in the female, dorsolateral prefrontal cortex, with a
wide increase in methylation in the maleGAL gene. Some ways that
these changes in the locus coeruleus might influence the develop-
ment of MDD are illustrated in Fig. 7.
In addition, the present study reports markedly different tran-
script levels for the four GAL family members with individual, re-
gional distribution patterns.GAL andGALR1mRNAs are the most
abundant transcripts, GALR1 mRNA being expressed at eightfold
higher levels in dorsolateral prefrontal cortex than in anterior cin-
gulate cortex (Table 2). Finally, the RIA shows major differences in
GAL peptide levels among the brain regions analyzed, paralleling
transcript levels and evidencing translation of the transcript. How-
ever, a sex difference could be detected, but only in the locus
coeruleus, where levels were higher in females.
These results are discussed in relation to our previous in situ
hybridization analysis describing the cellular localization of the
galanin system in the lower brainstem (locus coeruleus and dorsal
raphe nucleus) of the normal human postmortem brain (32). This
approach can suggest which neuron populations express the
transcripts and are the site of the methylations, here reported
based on qPCR and bisulfite pyrosequencing, i.e., biochemical
analyses (see below). For a comparison of the results in LeMaître,
et al. (32) and the present study, see SI Discussion, Comparison of
in Situ Hybridization and RT-qPCR Results.
GAL and MDD: Genome-Wide Association Studies. Two recent large
genome-wide association studies (GWAS) (68, 69) have analyzed
in-depth cohorts of MDD patients and controls. The first study,
investigating 2,431 cases and 3,673 controls, found a suggestive
association of GAL with MDD using a gene-based test, which
retained low-association P values in two additional independent
cohorts (68). However, in the second GWAS involving 9,240
MDD cases and 9,519 controls (at that time the largest GWAS
conducted), no SNP achieved genome-wide significance in either
the MDD discovery or the replication phase (69).
In addition, two recent huge GWAS analyzing depressive
symptoms (70) and self-reported depression (71), with tens of thou-
sands participants, could not support a role of the galanin system
genes within their top results. However, these GWAS did not
control for the well-known environmental risk factors of de-
pression (72). In fact, in the study by Juhasz, et al. (56) galanin
system gene variants altered the development of depression only
in people who also were exposed to strong stress, and no significant
effect of GAL and its receptors could be seen without taking stress
into account (SI Discussion, GAL and MDD: GWAS).
GAL and MDD: Candidate Gene and Gene-Environment Approach. A
recent candidate gene analysis based on self-reported questionnaires
from 2,361 individuals (∼70% females; ∼30% males) measuring
lifetime depression, depressive and anxiety symptoms, and life
stressors showed that gene variants for GAL and all three of its
receptors are associated with increased risk of lifetime and current
Fig. 4. Alterations in GAL gene expression and DNA methylation in the
locus coeruleus of male and female DS subjects. (A and E) Gene-expression
levels of GAL in the locus coeruleus of male (A) and female (E) controls and
DS subjects. (B–D and F–H) Percentage of DNA methylation levels at indi-
vidual CpG sites of the GAL gene in male (B–D) and female (F–H) controls and
DS subjects. All data are presented as mean ± SEM; males: n = 10 controls, 10
DS subjects; females: n = 12 controls, 10 DS subjects. Significant differences
between DS subjects and controls are indicated: *P < 0.05, **P < 0.01. CON,
controls; DS, depressed suicide.
Fig. 3. Alterations in GAL gene expression and DNA methylation in the
dorsal raphe nucleus of male and female DS subjects. (A and E ) Gene-
expression levels of GAL in the dorsal raphe nucleus of male (A) and female
(E) controls and DS subjects. (B–D and F–H) Percentage of DNA methylation
levels at individual CpG sites of the GAL gene in male (B–D) and female (F–H)
controls and DS subjects. All data are presented as mean ± SEM; males: n =
11 controls, 10 DS subjects; females: n = 11 controls, 10 DS subjects. Signif-
icant differences between DS subjects and controls are indicated: *P < 0.05,
**P < 0.01. CON, controls; DS, depressed suicide.
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depression and anxiety, but only after childhood adversity or recent
negative life events, suggesting that the galanin system genes alter
the development of depression through epigenetic mechanisms
(56). In agreement with this study, the present report reveals cor-
relations, mainly for GAL and GALR3, between transcript levels
and promoter methylation in several brain regions of both sexes
(SI Discussion, GAL and MDD: Candidate Gene Approach).
DNA Methylation. Methylation changes for the galanin system
have been described previously, mainly in studies on various
types of cancer, and were associated with tumor suppression (73, 74).
Here we report that DNA methylation of members of the galanin
system also may play a role in MDD. Analyzing three or four se-
lected CpG sites, we observed significant changes in the degree of
methylation at several sites in the dorsolateral prefrontal cortex,
dorsal raphe nucleus, and locus coeruleus of DS subjects compared
with controls. The changes in receptor methylation were associated
withGALR3 in the locus coeruleus and dorsal raphe nucleus, mainly
in female subjects. With some exceptions, there was an inverse
correlation between methylation and transcript levels, in agreement
with the view that methylation represses gene transcription (75) (SI
Discussion, DNA Methylation).
Transcription Factor-Binding Analysis. In many cases, DNA meth-
ylation of specific CpGs influences transcription factor binding.
Using the JASPER database (65, 66), we identified a number of
potential transcription factor-binding sites in the regions including
the differentially methylated CpG sites in GAL and GALR3.
Two of the transcription factors, specificity protein 1 (SP1) and
NEUROD2, regulate GAL expression in mouse (76, 77) and
potentially also in human (78). Further, SP1 binding is known to
be affected by DNA methylation (79). Both transcription factors
potentially bind to CpG2, which was hypermethylated in male
and hypomethylated in female DS subjects, corresponding to
decreased and increased mRNA expression, respectively. An
additional SP1-binding site was identified in the region including
CpG1. For GALR3, the transcription factors binding to the
identified sites have not been shown to be involved in the regula-
tion of this gene. Taken together, these findings strengthen the
notion that the observed epigenetic and gene-expression changes
are connected and open the way for mechanistic studies to un-
derstand the regulation of these genes in depth.
Locus Coeruleus and Dorsal Raphe Nucleus. The locus coeruleus and
dorsal raphe nucleus regions in the rat lower brainstem harbor
NA and 5-HT cell bodies, respectively (80) and are key nodes in
the mood circuitry. Both the GAL and GALR3 transcripts in the
locus coeruleus samples are expressed mainly in the noradren-
ergic neurons (32); thus they are likely to be the sites for the
regulation of transcripts and the methylation shown in the
present study.
The dorsal raphe nucleus, where 50–70% of all neurons in
rodents are nonserotonergic (81–83), can be discussed in a
similar way: The monitored GAL and GALR1 mRNAs may not be
present in 5-HT neurons, but GALR3 likely is present. However,
both GAL and GALR1 transcripts have been observed in the close
vicinity of the 5-HT neurons (32). Thus the changes in GAL mRNA
and methylation likely occur in nonserotonin cells. Interestingly, the
up-regulation ofGALR1mRNA in the ventral periaqueductal gray is
in agreement with two recent experimental studies on male rats that
showed an increase in GALR1 mRNA levels (likely not in 5-HT
neurons) after mild, blast-induced traumatic brain injury (84) and
chronic mild stress (85). For a discussion of medullary raphe nuclei,
see SI Discussion, Medullary Raphe Nuclei. However, we note here
that in this region there is an increase inGAL andGALR3 transcript
Fig. 5. Alterations in GALR3 gene expression and DNA methylation in the
dorsal raphe nucleus of male and female DS subjects. (A and E) Gene-expression
levels of GALR3 in the dorsal raphe nucleus of male (A) and female (E) controls
and DS subjects. (B–D and F–H) Percentage of DNA methylation levels at indi-
vidual CpG sites of the GALR3 gene in male (B–D) and female (F–H) controls and
DS subjects. All data are presented asmean ± SEM; males: n = 11 controls, 10 DS
subjects; females: n = 11 controls, 10 DS subjects. Significant differences be-
tween DS subjects and controls are indicated: *P < 0.05, **P < 0.01. CON,
controls; DS, depressed suicide.
Table 3. Overview of mRNA and DNA methylation changes
GAL GALR1 GALR2 GALR3
gDNA methylation gDNA methylation gDNA methylation gDNA methylation
Regions Sex mRNA CpG1 CpG2 CpG3 mRNA CpG1 CpG2 CpG3 CpG4 mRNA CpG1 CpG2 CpG3 CpG4 mRNA CpG1 CpG2 CpG3
DLPFC M ↓↓ ↑ ↑↑ ↑↑ ↑ — — — — — — — — — ↓↓ — — —
F ↑ ↑ ↓ — ↑ — — — — — — — — — — — — —
ACC M — — — — — — — — — — — — — — — — — —
F — — — — — — — — — — — — — — — — — —
DRN M ↑↑ — ↓ ↑ — — — — — — — — — ↑ — — —
F ↑↑ — — — — — — — — — — — — — ↑↑ ↓↓ ↓↓ —
LC M ↑↑ ↓↓ ↓ — — — — — — — — — — — ↑ ↓ —
F ↑↑ ↓ ↓↓ — — — — — — — — — — — ↑↑ ↓ ↓↓ —
MRN M ↑ — — — ↑ — — — — ↓↓ — — — — ↑ — — —
F ↑ — — — — — — — — — — — — ↑ — — —
The arrows represent statistical significance; upward arrows signify increased in gene expression and methylation status, and downward arrows signify
decreased gene expression and methylation status. A single arrow represents P < 0.05, and two arrows represent P < 0.01. ACC, anterior cingulate cortex;
DLPFC, dorsolateral prefrontal cortex; DRN, dorsal raphe nucleus; LC, locus coeruleus; MRN, medullary raphe nucleus.
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levels in males and females and in GALR1 transcript levels in males
only, as well as a robust decrease inGALR2mRNA in males only; in
fact, this is the only region showing a change in this receptor tran-
script. No effects on DNA methylation were recorded.
Prefrontal Cortex.A number of symptoms and diagnostic markers
of MDD have been associated with prefrontal cortex, including
decreased gray matter volume, hypermetabolism, and spine
morphology (86). We observed distinct decreases in GAL and
GALR3 mRNA levels in the dorsolateral prefrontal cortex of DS
males, with increased methylation at three sites of theGAL gene,
the reverse of the effects seen in locus coeruleus and dorsal ra-
phe nucleus. In contrast, GAL mRNA is up-regulated in this
region in female DS subjects; this up-regulation is the only sex
difference for the GAL transcript seen in the qPCR analysis and
requires further analysis. However, no changes were detected in
another, closely related cortical area, the anterior cingulate
cortex, which also has been consistently implicated in depression
and suicide (87). Interestingly, although the average levels for
GAL, GALR2, and GALR3 transcripts are approximately similar
in the cortical regions, GALR1 mRNA levels are around eight-
fold higher in dorsolateral prefrontal cortex than in anterior
cingulate cortex.
The findings in the prefrontal cortex are difficult to interpret,
because we have no information on the cells expressing GAL
system members in human dorsolateral prefrontal and anterior
cingulate cortices. In principle, however, the mechanistic effects
of GAL release should be equally mediated by GAL1 and GAL3,
because both exhibit a similar (nanomolar) affinity for GAL (88).
Therefore the differences will depend on which neuron subtype
expresses the receptor and on the coupling to intracellular
signaling cascades.
In general, peptides in the cortical region are detected in in-
terneurons (89), but many pyramidal neurons express the transcript
for cholecystokinin (90) and the peptide itself (91). Quantitative
autoradiographic 125I-GAL–binding studies showed a strong corti-
cal binding in the human brain (39, 41), in sharp contrast with the
rat brain, which lacks 125I-GAL binding in dorsal cortical and
hippocampal areas (37, 38). However, 125I-GAL(1-15ol) binds to
these regions (92), and GAL(1-15) hyperpolarizes hippocampal C3
neurons (93). Investigation of these findings is continuing (SI
Discussion, Dorsolateral Prefrontal Cortex) (94).
As for the mechanism(s) involved, one may speculate that the
increased GAL mRNA levels in the locus coeruleus result in up-
regulated GAL synthesis, enhanced centrifugal, axonal GAL
transport, and increased GAL release in dorsolateral prefrontal
cortex (Fig. 7). Here, in a possibly desensitizing process, GAL
may down-regulate GALR3 expression in cortical projections
and/or interneurons.
Functional Significance. It has been suggested that epigenetic
mechanisms, such as DNA methylation, may be involved in
psychiatric disorders (95, 96) and play an important role in stress
and depression (7, 97). Here CpG methylation, catalyzed by
DNA methyltransferases, in general represses gene transcription
(75). We focus the discussion on the NA/locus coeruleus system
and the prefrontal cortex. The role of NA vs. GAL has been
discussed by Kuteeva, et al. (54).
Animal Studies in the Locus Coeruleus. Early experimental evidence
suggested that locus coeruleus neurons in rats are activated by
stress, resulting in increased NA synthesis and NA release in the
forebrain (98–100). Stress also increases GAL expression in this
nucleus (101, 102). In general terms neuropeptides are released
following increased/burst firing (103, 104), also in the forebrain
(105, 106). Thus, stress and increased/burst firing likely causes
GAL release from nerve terminals in the forebrain as well as from
soma/dendrites of the locus coeruleus neurons. Peptide release
from soma/dendrites was first shown for oxytocin/vasopressin in
magnocellular neurons in the hypothalamic paraventricular nu-
cleus (107) and may be relevant for GAL in the locus coeruleus
also (108).
Rat locus coeruleus neurons express GALR1 mRNA (42, 43),
and, as evidenced by electrophysiological studies (109), this re-
ceptor is likely functional in this site, mediating hyperpolarization
(46, 110). Thus, somato-dendritically released GAL may inhibit
firing via a GAL1 autoreceptor, hypothetically to prevent over-
excitation (54). In agreement, results from a study on a transgenic
mouse overexpressing GAL under the dopamine β-hydroxylase
promoter with a fivefold increase in GAL mRNA in the locus
coeruleus (111) suggest that GAL is important for modulating
anxiety states driven by high noradrenergic signaling (112).
The Human Locus Coeruleus. In trying to translate the animal ex-
perimental scenario to humans and MDD, one could argue that
Fig. 6. Alterations in GALR3 gene expression and DNA methylation in the
locus coeruleus of male and female DS subjects. (A and E) Gene expression
levels of GALR3 in the locus coeruleus of male (A) and female (E) controls
and DS subjects. (B–D and F–H) Percentage of DNA methylation levels at
individual CpG sites of the GALR3 gene in male (B–D) and female (F–H)
controls and DS subjects. All data are presented as mean ± SEM; males: n =
10 controls, 10 DS subjects; females: n = 12 controls, 10 DS subjects. Signif-
icant differences between DS subjects and controls are indicated: *P < 0.05,
**P < 0.01. CON, controls; DS, depressed suicide.
Table 4. Concentration of GAL (picomoles per milligram ± SEM) in the different regions
analyzed by RIA
Subject DLPFC ACC DRN LC MRN
Male controls 3.89 ± 1.21 5.35 ± 1.15 61.58 ± 13.74 31.80 ± 7.46 15.65 ± 2.32
Male DS subjects 2.68 ± 0.52 4.94 ± 0.96 68.14 ± 11.6 37.39 ± 10.71 18.73 ± 4.76
Female controls 1.70 ± 0.38 6.37 ± 1.79 80.62 ± 10.24 43.35 ± 6.33 15.45 ± 3.53
Female DS subjects 1.33 ± 0.29 5.97 ± 1.32 81.61 ± 5.19 67.68 ± 7.47 13.55 ± 2.95
ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DRN, dorsal raphe nucleus; LC, locus
coeruleus; MRN, medullary raphe nucleus.
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(i) GAL3 seems to have replaced GAR1 in human locus coeruleus
neurons (32); (ii) hyperpolarization is one transduction mechanism
for GAL1 and also may be the transduction mechanism for GAL3
(46, 88, 110); and (iii) GAL and GALR3 transcripts are increased
in the locus coeruleus of DS subjects’ brains. It may be speculated
that chronic stress and, as a consequence, constant and persistent
inhibition of the NA-locus coeruleus neurons by GALmay result in
reduced NA levels in the forebrain regions involved in mood
control, e.g., the dorsolateral prefrontal cortex and anterior cin-
gulate cortex; reduced NA levels are a characteristic feature of
mood-related disorders. Together with a genetic vulnerability (lack
of resilience), this reduction in NA levels may contribute to the
symptoms encountered in such disorders (Fig. 7).
Prefrontal Cortex. In the prefrontal cortex, reciprocal interactions
between the dorsolateral prefrontal cortex and anterior cingulate
cortex, as well as between the anterior cingulate cortex and amyg-
dala, have been described, whereby MDD subjects show reduced
functional connectivity between the dorsolateral prefrontal cor-
tex and anterior cingulate cortex (87). The transcript levels of all
four GAL members are very similar in the two regions, except
that (i) GALR1 mRNA levels are eightfold higher in the
dorsolateral prefrontal cortex than in the anterior cingulate cortex
and (ii) the differences between MDD and controls are mainly
for GAL and are found only in male dorsolateral prefrontal
cortex, indicating that any prefrontal cortical GALergic mecha-
nisms in MDD are associated with GAL and GALR3 in this
region and sex (SI Discussion, Dorsolateral Prefrontal Cortex). Of
note, the apparent differences in GAL concentrations in this
region between normal male and female controls did not reach
significance but may still be taken as support for sex having an
influence on information processing in this cortical region.
Treatment of MDD with Neuropeptides. Neuropeptide receptors may
be promising targets for drug development in general because, as
mentioned previously, they are primarily released upon high-
frequency/burst firing (103, 104) that may occur in a selectively chal-
lenged, pathologically afflicted system (16, 113). Therefore,
the antagonist will block only an overactivated signaling pathway, not
affecting other silent or moderately active (no peptide release) systems
producing the same ligand, and thus resulting in fewer side effects.
Treatment of depression with neuropeptide antagonists has
been considered previously (15–19, 114). In fact, an initial report
on the administration of a substance P/neurokinin 1 antagonist
showed a significant efficacy vs. placebo, without side effects
(115). This result could not be reproduced in an expanded phase
3 study (15, 116); however, clinical work on neurokinin antago-
nists is ongoing (117, 118).
Treatment of MDD with GAL Ligands. Both GAL and GAL3 are up-
regulated in the locus coeruleus and dorsal raphe nucleus of MDD
patients, possibly resulting in attenuated NA and 5-HT release in the
forebrain. Treatment with a GAL3 antagonist could, by disinhibition,
have antidepressant activity, restoring NA and 5-HT levels in these
brain regions, just as SNRIs do. Moreover, it may be speculated that
the well-known delay in the onset of SSRIs’ effect caused by the
activation of somatic, inhibitory 5-HT1A receptors (8, 58) may not
occur with GAL3 antagonists. Also, GAL3 signaling in some other
brain regions, e.g., the dorsolateral prefrontal cortex, likely will not
be affected, because our study shows thatGAL andGALR3mRNA
are unchanged (in females) or even down-regulated (in males),
possibly excluding GAL system-related side effects. Moreover, the
regionally selective effect of a GAL3 antagonist should compare
favorably with SSRIs, SNRIs, and NRIs, which increase extracellular
monoamine levels in all regions that monoamine neurons innervate,
i.e., essentially throughout the entire nervous system. In fact, small-
molecule, blood–brain barrier-penetrating GalR3 antagonists have
been generated (119, 120). The extent to which such an antagonist
would act via mechanisms different from those of SNRIs and
Fig. 7. The locus coeruleus (LC) pathway to cortex and its involvement in stress. Many neurons in the locus coeruleus coexpress NA and GAL. In rats, under normal
circumstances these neurons fire spontaneously in a slow and regular fashion (124), but in response to stress they react with increased activity and burst firing (100).
NA is stored primarily in synaptic vesicles and is released at low activity and more so after stress (98, 99), acting on adrenoreceptors (ARs). GAL is stored only in large,
dense core (LDC) vesicles and is released extrasynaptically (125) in response to increased/burst firing (106) from these vesicles in nerve endings in the forebrain. In
humans (this study), GAL may, e.g., activate inhibitory postsynaptic GAL1 receptors (GalR1) on neurons in the dorsolateral prefrontal cortex (DLPFC) and anterior
cingulate cortex (ACC). Presumably, release also can occur from dendrites/soma in the locus coeruleus, activating inhibitory GAL3 autoreceptors (GalR3). It is hy-
pothesized that under excessive/chronic stress GAL induces a long-lasting inhibition of NA neurons and thus of NA release in forebrain regions such as the dor-
solateral prefrontal cortex and anterior cingulate cortex, contributing to the development of MDD. Not included are changes in GAL, GALR1, and GALR3 mRNA
levels in the dorsolateral prefrontal cortex.
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whether the currently used antidepressant drugs act via the GAL
system has been discussed (121).
Limitations. Several limitations are associated with the present
study. They are discussed in some detail in SI Discussion, Limi-
tations and encompass (i) concerns about GAL3, including its
transduction mechanism(s) [this receptor has emerged as a
complex receptor lacking well-defined signaling properties,
contrasting GAL1 and GAL2 (36); so far there is no evidence
that GAL3 is involved in receptor di- or heterodimerization
(45)]; (ii) the lack of information about the protein, because only
the transcripts for the receptors have been studied; (iii) the
modest, albeit significant, changes in transcript mRNA levels;
(iv) the relatively low number of postmortem brains analyzed;
(v) the incomplete knowledge (in some instances) of the identity
of the neurons expressing the transcripts (and thus of the site
where methylation occurs); for example, the study by Le Maître,
et al. (32) was not systematic, and galanin–5-HT coexistence in
regions not analyzed cannot be excluded; and (vi) the general
low sensitivity of histochemical techniques; this low sensitivity
may have been an issue when Le Maître, et al. (32) could not
detect the GAL1 transcript in the locus coeruleus with in situ
hybridization, whereas the present qPCR analysis showed high
levels of this transcript in this region; (vii) the superficial in-
vestigation of methylation sites and their functional significance;
and (viii) the influence of treatment with various drugs (Table
S1), which requires further investigation (also see ref. 121).
Concluding Remarks. The present results, based on the analysis of
five human brain regions, suggest the GAL system is involved
in MDD. Interestingly, exactly 40 y ago Asberg and colleagues (122)
reported that significantly lower concentrations of the 5-HT me-
tabolite 5-hydroxyindoleacetic acid (5-HIAA) in the cerebrospinal
fluid are associated with a very high rate of serious suicidal attempts,
opening the way for the development of SSRIs aimed at elevating
extraneuronal 5-HT levels. This class of drugs then replaced the
monoamine oxidase inhibitors and the tricyclic antidepressants.
It is important to note that many overlapping transmitter
systems exist and, in a way similar to the GAL family, may be in-
volved in MDD psychopathology. The available detailed knowledge
of the cellular organization and transmitter receptor architecture of
the human prefrontal cortex, two subregions of which are studied
here, provides a broad perspective on the present work and also
shows how much research still needs to be carried out (123).
Materials and Methods
Brain Samples. Postmortem brain tissue was obtained from the Douglas-Bell
Canada Brain Bank. A total of 212 punched samples from five different brain
regions was included (Table 1). Ethical approval for this study was obtained
from the Institutional Review Board of the Douglas Mental Health University
Institute, with written informed consent from the families. The Regional Ethical
Board in Stockholm has granted The Karolinska Institutet group permission
no. 2013/474-31/2 for processing postmortem brain samples (SI Materials and
Methods, Brain Samples and Table S1).
RNA Isolation and Integrity Analysis. Total RNA was isolated using the RNeasy
PlusMini Kit. RNAquantity andqualitywere determined spectrophotometrically
by using a ND1000 nanodrop. RNA integrity was checked using Experion au-
tomated electrophoresis system (Bio-Rad Laboratories). Total RNA was reverse
transcribed to generate cDNA using a High-Capacity Reverse Transcription Kit
(Life Technologies) (SI Materials and Methods).
RT-qPCR. qPCR was performed as described previously (SI Materials and
Methods) (32).
Genomic DNA Extraction and PyroMark PCR. Genomic DNA (gDNA) was isolated
by using the DNeasy Blood and Tissue Kit (Qiagen), checked spectrophoto-
metrically, and bisulfite-converted by using the EZ DNA Methylation-Gold Kit
(Zymo Research). Converted DNA was subject to 40 cycles of amplification by
using gene-specific primers and the pyroPCR PyroMark (Qiagen) kit (SIMaterials
and Methods).
Bisulfite Pyrosequencing. Bisulfite pyrosequencing was performed using
PyroMark Q96 ID (Qiagen) according to the manufacturer’s protocol and as
previously described (122). Primer sequences are listed in Fig. S6B, and the ge-
nomic locations of the CpGs analyzed are shown in Fig. S6A; also see SI Ma-
terials and Methods.
RIA. Human GAL was measured using antiserum G-026-01 (Phoenix Europe
GmbH) raised in a rabbit against human GAL (SI Materials and Methods).
Statistical Analysis. Statistical analysis was performed with GraphPad Prism 6
(GraphPad Software), StatView (SAS Institute Inc.), and Systat 11 (Systat
Software, Inc.). RIN, age, PMI, and tissue pH values for the five brain regions in
controls and DS subjects were analyzed bymultivariate ANOVA and two-tailed t
test for independent groups. The Shapiro–Wilks test was used to test for
Gaussian distribution. Significant outliers for qPCR fold change and percent
methylation were analyzed by the ROUT (robust regression followed by outlier
identification) method and were excluded if P < 0.05. qPCR data were analyzed
by using the nonparametric Mann–Whitney U test. Differences in DNA meth-
ylation between controls and suicides were analyzed using the Mann–Whitney
U test. P values below 0.05 were considered significant, and P values between
0.05 and 0.1 were considered to represent a trend.
ACKNOWLEDGMENTS. We thank Drs. Tamas Bartfai (Stockholm University
and Oxford University), Jean-Pierre Changeux (Institut Pasteur), Wayne
C. Drevets (Janssen Research and Development), Eric Kandel (Columbia Uni-
versity), Diego Pizzagalli (McLean Hospital), and Sol Snyder (Johns Hopkins
University) for valuable comments and suggestions. This project presently is
supported by Swedish Research Council Grant 04X-2887 (to T.G.M.H.); the
Swedish Brain Foundation (T.G.M.H.); and by grants from Karolinska Institutet
(to T.G.M.H.) and the Swedish Research Council for Environment, Agricultural
Sciences, and Spatial Planning (Formas) (to J.R.). Earlier phases of this project
were supported by a National Association for Research on Schizophrenia and
Depression Distinguished Investigator Award (2009) (to T.G.M.H.), the Euro-
pean Union Framework 6 Integrated Project New-Mood LSHM-CT-2004-
503474 (2004–2008) (to G.B., G.J., and T.G.M.H.), AFA Insurance (2008) (T.G.M.H.),
and by a 5-y unrestricted Bristol-Myers-Squibb Grant in Neuroscience (to
T.G.M.H.). Of particular importance were generous grants over a longer pe-
riod from the Marianne and Marcus Wallenberg Foundation (1998–2009) and
from the Knut and Alice Wallenberg Foundation (to T.G.M.H.). N.M. is a Cana-
dian Institute of Health Research New Investigator and Fonds de la Recherche en
Santé du Québec (FRQ-S) Chercheur-boursier. The Douglas–Bell Canada Brain
Bank is supported by the Réseau Québécois sur le Suicide, les Troubles
de l’Humeur et les Troubles Associés (FRQ-S) and by a Platform Support Grant
from Brain Canada (to N.M.). Support was provided by theMagyar Tudományos
Akadémia (MTA)–Semmelweis Egyetem (SE)–Nemzeti Agykutatási Program
(NAP) B alprogram Genetic Brain Imaging Migraine Research Group through
Kutatási és Technológiai Innovációs Alap (KTIA) (Grant KTIA_NAP_13-2-2015-
0001, to G.J.); by the NAP A-SE Research Group (Grant KTIA_NAP_13-1-2013-
0001, to G.B.) and (Grant KTIA_13_NAP-A-II/14, to G.B.); and by the MTA-SE
Neuropsychopharmacology and Neurochemistry Research Group (G.B.).
1. Kessler RC, et al.; National Comorbidity Survey Replication (2003) The epidemiology
of major depressive disorder: Results from the National Comorbidity Survey Repli-
cation (NCS-R). JAMA 289(23):3095–3105.
2. Wittchen HU, et al. (2011) The size and burden of mental disorders and other
disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(9):
655–679.
3. de Kloet ER, Joëls M, Holsboer F (2005) Stress and the brain: From adaptation to
disease. Nat Rev Neurosci 6(6):463–475.
4. Nestler EJ, et al. (2002) Neurobiology of depression. Neuron 34(1):13–25.
5. McEwen BS (2008) Central effects of stress hormones in health and disease: Un-
derstanding the protective and damaging effects of stress and stress mediators. Eur J
Pharmacol 583(2-3):174–185.
6. Labonté B, et al. (2013) Genome-wide methylation changes in the brains of suicide
completers. Am J Psychiatry 170(5):511–520.
7. Vialou V, Feng J, Robison AJ, Nestler EJ (2013) Epigenetic mechanisms of depression
and antidepressant action. Annu Rev Pharmacol Toxicol 53:59–87.
8. Blier P, de Montigny C (1994) Current advances and trends in the treatment of de-
pression. Trends Pharmacol Sci 15(7):220–226.
9. Millan MJ (2006) Multi-target strategies for the improved treatment of depressive
states: Conceptual foundations and neuronal substrates, drug discovery and thera-
peutic application. Pharmacol Ther 110(2):135–370.
10. Gardier AM, Malagié I, Trillat AC, Jacquot C, Artigas F (1996) Role of 5-HT1A autor-
eceptors in the mechanism of action of serotoninergic antidepressant drugs: Recent
findings from in vivo microdialysis studies. Fundam Clin Pharmacol 10(1):16–27.
Barde et al. PNAS | Published online December 9, 2016 | E8479
N
EU
RO
SC
IE
N
CE
PN
A
S
PL
U
S
11. Millan MJ, Goodwin GM, Meyer-Lindenberg A, Ove Ögren S (2015) Learning from
the past and looking to the future: Emerging perspectives for improving the
treatment of psychiatric disorders. Eur Neuropsychopharmacol 25(5):599–656.
12. Trivedi MH, et al.; STAR*D Study Team (2006) Evaluation of outcomes with cit-
alopram for depression using measurement-based care in STAR*D: Implications for
clinical practice. Am J Psychiatry 163(1):28–40.
13. Montgomery SA (2006) Why do we need new and better antidepressants? Int Clin
Psychopharmacol 21(Suppl 1):S1–S10.
14. Artigas F (2015) Developments in the field of antidepressants, where do we go now?
Eur Neuropsychopharmacol 25(5):657–670.
15. Griebel G, Holsboer F (2012) Neuropeptide receptor ligands as drugs for psychiatric
diseases: The end of the beginning? Nat Rev Drug Discov 11(6):462–478.
16. Hökfelt T, Bartfai T, Bloom F (2003) Neuropeptides: Opportunities for drug discov-
ery. Lancet Neurol 2(8):463–472.
17. Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G (2003) Neuropeptide systems
as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol
Sci 24(11):580–588.
18. Maubach KA, Rupniak NM, Kramer MS, Hill RG (1999) Novel strategies for phar-
macotherapy of depression. Curr Opin Chem Biol 3(4):481–488.
19. Nemeroff CB, Vale WW (2005) The neurobiology of depression: Inroads to treatment
and new drug discovery. J Clin Psychiatry 66(Suppl 7):5–13.
20. Burbach JP (2010) Neuropeptides from concept to online database. www.neuropeptides.
nl. Eur J Pharmacol 626(1):27–48.
21. Tatemoto K, Rökaeus A, Jörnvall H, McDonald TJ, Mutt V (1983) Galanin - a novel
biologically active peptide from porcine intestine. FEBS Lett 164(1):124–128.
22. Rökaeus A, et al. (1984) A galanin-like peptide in the central nervous system and
intestine of the rat. Neurosci Lett 47(2):161–166.
23. Skofitsch G, Jacobowitz DM (1985) Immunohistochemical mapping of galanin-like
neurons in the rat central nervous system. Peptides 6(3):509–546.
24. Skofitsch G, Jacobowitz DM (1986) Quantitative distribution of galanin-like immu-
noreactivity in the rat central nervous system. Peptides 7(4):609–613.
25. Melander T, Hökfelt T, Rökaeus A (1986) Distribution of galaninlike immunoreac-
tivity in the rat central nervous system. J Comp Neurol 248(4):475–517.
26. Kordower JH, Le HK, Mufson EJ (1992) Galanin immunoreactivity in the primate
central nervous system. J Comp Neurol 319(4):479–500.
27. Holets VR, Hökfelt T, Rökaeus A, Terenius L, Goldstein M (1988) Locus coeruleus
neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and
their efferent projections to the spinal cord, cerebral cortex and hypothalamus.
Neuroscience 24(3):893–906.
28. Melander T, et al. (1986) Coexistence of galanin-like immunoreactivity with cat-
echolamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS.
J Neurosci 6(12):3640–3654.
29. Xu ZQ, Shi TJ, Hökfelt T (1998) Galanin/GMAP- and NPY-like immunoreactivities in
locus coeruleus and noradrenergic nerve terminals in the hippocampal formation
and cortex with notes on the galanin-R1 and -R2 receptors. J Comp Neurol 392(2):
227–251.
30. Chan-Palay V, Jentsch B, Lang W, Höchli M, Asan E (1990) Distribution of neuro-
peptide Y, C-terminal flanking peptide of NPY and galanin and coexistence with
catecholamine in the locus coeruleus of normal human, Alzheimer’s nementia and
Parkinson’s disease brains. Dementia 1:18–31.
31. Miller MA, Kolb PE, Leverenz JB, Peskind ER, Raskind MA (1999) Preservation of
noradrenergic neurons in the locus ceruleus that coexpress galanin mRNA in Alz-
heimer’s disease. J Neurochem 73(5):2028–2036.
32. Le Maître E, Barde SS, Palkovits M, Diaz-Heijtz R, Hökfelt TG (2013) Distinct features
of neurotransmitter systems in the human brain with focus on the galanin system in
locus coeruleus and dorsal raphe. Proc Natl Acad Sci USA 110(6):E536–E545.
33. Lu X, et al. (2005) A role for galanin in antidepressant actions with a focus on the
dorsal raphe nucleus. Proc Natl Acad Sci USA 102(3):874–879.
34. Fuxe KAL, et al. (1990) Galanin/5-HT receptor interactions. A new integrative
mechanism in the control of 5-HT neurotransmission in the central nervous system.
Serotonin, eds Paoletti R, Vanhoutte PM, Brunello N, Maggi FM (Springer, Dor-
drecht, The Netherlands), pp 169–185.
35. Habert-Ortoli E, Amiranoff B, Loquet I, Laburthe M, Mayaux JF (1994) Molecular
cloning of a functional human galanin receptor. Proc Natl Acad Sci USA 91(21):
9780–9783.
36. Lang R, et al. (2015) Physiology, signaling, and pharmacology of galanin peptides
and receptors: Three decades of emerging diversity. Pharmacol Rev 67(1):118–175.
37. Skofitsch G, Sills MA, Jacobowitz DM (1986) Autoradiographic distribution of 125I-
galanin binding sites in the rat central nervous system. Peptides 7(6):1029–1042.
38. Melander T, et al. (1988) Autoradiographic quantitation and anatomical mapping of
125I-galanin binding sites in the rat central nervous system. J Chem Neuroanat 1(4):
213–233.
39. Köhler C, et al. (1989) Distribution of galanin-binding sites in the monkey and hu-
man telencephalon: Preliminary observations. Exp Brain Res 75(2):375–380.
40. Köhler C, Hallman H, Melander T, Hökfelt T, Norheim E (1989) Autoradiographic
mapping of galanin receptors in the monkey brain. J Chem Neuroanat 2(5):269–284.
41. Köhler C, Chan-Palay V (1990) Galanin receptors in the post-mortem human brain.
Regional distribution of 125I-galanin binding sites using the method of in vitro re-
ceptor autoradiography. Neurosci Lett 120(2):179–182.
42. O’Donnell D, Ahmad S, Wahlestedt C, Walker P (1999) Expression of the novel gal-
anin receptor subtype GALR2 in the adult rat CNS: Distinct distribution from GALR1.
J Comp Neurol 409(3):469–481.
43. Burazin TC, Larm JA, Ryan MC, Gundlach AL (2000) Galanin-R1 and -R2 receptor
mRNA expression during the development of rat brain suggests differential subtype
involvement in synaptic transmission and plasticity. Eur J Neurosci 12(8):2901–2917.
44. Mennicken F, Hoffert C, Pelletier M, Ahmad S, O’Donnell D (2002) Restricted dis-
tribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system.
J Chem Neuroanat 24(4):257–268.
45. Fuxe K, et al. (2012) On the existence and function of galanin receptor heteromers in
the central nervous system. Front Endocrinol (Lausanne) 3:127.
46. Wang S, et al. (1997) Genomic organization and functional characterization of the
mouse GalR1 galanin receptor. FEBS Lett 411(2-3):225–230.
47. Fuxe K, et al. (1998) Galanin modulates 5-hydroxytryptamine functions. Focus on
galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the
brain. Ann N Y Acad Sci 863:274–290.
48. Fuxe K, et al. (1991) Galanin/5-HT interactions in the rat central nervous system.
Relevance for depression. Galanin: A New Multifunctional Peptide in the Neuro-
endocrine System, eds Hökfelt T, Bartfai T, Jacobowitz D, Ottoson D (Macmillan
Education UK, London), pp 221–235.
49. Weiss JM, Bonsall RW, Demetrikopoulos MK, Emery MS, West CH (1998) Galanin: A
significant role in depression? Ann N Y Acad Sci 863:364–382.
50. Wrenn CC, Crawley JN (2001) Pharmacological evidence supporting a role for gal-
anin in cognition and affect. Prog Neuropsychopharmacol Biol Psychiatry 25(1):
283–299.
51. Barrera G, et al. (2005) One for all or one for one: Does co-transmission unify the
concept of a brain galanin “system” or clarify any consistent role in anxiety?
Neuropeptides 39(3):289–292.
52. Brunner SM, et al. (2014) GAL3 receptor KO mice exhibit an anxiety-like phenotype.
Proc Natl Acad Sci USA 111(19):7138–7143.
53. Holmes A, Picciotto MR (2006) Galanin: A novel therapeutic target for depression,
anxiety disorders and drug addiction? CNS Neurol Disord Drug Targets 5(2):225–232.
54. Kuteeva E, Hökfelt T, Wardi T, Ögren SO (2010) Galanin, galanin receptor subtypes
and depression-like behaviour. EXS 102:163–181.
55. Bing O, Möller C, Engel JA, Söderpalm B, Heilig M (1993) Anxiolytic-like action of
centrally administered galanin. Neurosci Lett 164(1-2):17–20.
56. Juhasz G, et al. (2014) Brain galanin system genes interact with life stresses in
depression-related phenotypes. Proc Natl Acad Sci USA 111(16):E1666–E1673.
57. Albert PR, Lembo P, Storring JM, Charest A, Saucier C (1996) The 5-HT1A receptor:
Signaling, desensitization, and gene transcription. Neuropsychopharmacol 14(1):
19–25.
58. Artigas F, Bel N, Casanovas JM, Romero L (1996) Adaptative changes of the sero-
tonergic system after antidepressant treatments. Adv Exp Med Biol 398:51–59.
59. Stockmeier CA, et al. (1998) Increase in serotonin-1A autoreceptors in the midbrain
of suicide victims with major depression-postmortem evidence for decreased sero-
tonin activity. J Neurosci 18(18):7394–7401.
60. Drevets WC, et al. (2000) Serotonin type-1A receptor imaging in depression. Nucl
Med Biol 27(5):499–507.
61. Gassen NC, et al. (2015) Chaperoning epigenetics: FKBP51 decreases the activity of
DNMT1 and mediates epigenetic effects of the antidepressant paroxetine. Sci Signal
8(404):ra119.
62. Zimmermann N, et al. (2012) Antidepressants inhibit DNA methyltransferase 1
through reducing G9a levels. Biochem J 448(1):93–102.
63. Bach-Mizrachi H, et al. (2006) Neuronal tryptophan hydroxylase mRNA expression in
the human dorsal and median raphe nuclei: Major depression and suicide.
Neuropsychopharmacol 31(4):814–824.
64. UnderwoodMD, et al. (1999) Morphometry of the dorsal raphe nucleus serotonergic
neurons in suicide victims. Biol Psychiatry 46(4):473–483.
65. Jaspar M, et al. (2016) Influence of comt genotype on antero-posterior cortical
functional connectivity underlying interference resolution. Cereb Cortex 26(2):
498–509.
66. Mathelier A, et al. (2016) JASPAR 2016: A major expansion and update of the open-
access database of transcription factor binding profiles. Nucleic Acids Res 44(D1):
D110–D115.
67. Land T, Langel U, Bartfai T (1991) Hypothalamic degradation of galanin(1-29) and
galanin(1-16): Identification and characterization of the peptidolytic products. Brain
Res 558(2):245–250.
68. Wray NR, et al. (2012) Genome-wide association study of major depressive disorder:
New results, meta-analysis, and lessons learned. Mol Psychiatry 17(1):36–48.
69. Ripke S, et al.; Major Depressive Disorder Working Group of the Psychiatric GWAS
Consortium (2013) A mega-analysis of genome-wide association studies for major
depressive disorder. Mol Psychiatry 18(4):497–511.
70. Okbay A, et al.; LifeLines Cohort Study (2016) Genetic variants associated with
subjective well-being, depressive symptoms, and neuroticism identified through
genome-wide analyses. Nat Genet 48(6):624–633.
71. Hyde CL, et al. (2016) Identification of 15 genetic loci associated with risk of major
depression in individuals of European descent. Nat Genet 48(9):1031–1036.
72. Kendler KS, Gardner CO (2016) Depressive vulnerability, stressful life events and
episode onset of major depression: A longitudinal model. Psychol Med 46(9):
1865–1874.
73. Misawa K, et al. (2008) Epigenetic inactivation of galanin receptor 1 in head and
neck cancer. Clin Cancer Res 14(23):7604–7613.
74. Doufekas K, et al. (2013) GALR1 methylation in vaginal swabs is highly accurate in
identifying women with endometrial cancer. Int J Gynecol Cancer 23(6):1050–1055.
75. Moore LD, Le T, Fan G (2013) DNA methylation and its basic function.
Neuropsychopharmacol 38(4):23–38.
76. Bröhl D, et al. (2008) A transcriptional network coordinately determines transmitter
and peptidergic fate in the dorsal spinal cord. Dev Biol 322(2):381–393.
77. Gonzalez S, Binato R, Guida L, Mencalha AL, Abdelhay E (2014) Conserved tran-
scription factor binding sites suggest an activator basal promoter and a distal in-
hibitor in the galanin gene promoter in mouse ES cells. Gene 538(2):228–234.
E8480 | www.pnas.org/cgi/doi/10.1073/pnas.1617824113 Barde et al.
78. Kofler B, et al. (1995) Characterization of the 5′-flanking region of the human
preprogalanin gene. DNA Cell Biol 14(4):321–329.
79. Rüegg J, et al. (2011) Epigenetic regulation of glucose transporter 4 by estrogen
receptor β. Mol Endocrinol 25(12):2017–2028.
80. Dahlstrom A, Fuxe K (1964) Evidence for the existence of monoamine-containing
neurons in the central nervous system. I. Demonstration of monoamines in the cell
bodies of brain stem neurons. Acta Physiol Scand Suppl Suppl 232:1–55.
81. Fu W, et al. (2010) Chemical neuroanatomy of the dorsal raphe nucleus and adjacent
structures of the mouse brain. J Comp Neurol 518(17):3464–3494.
82. Lein ES, et al. (2007) Genome-wide atlas of gene expression in the adult mouse brain.
Nature 445(7124):168–176.
83. Smith GS, et al. (1994) Distribution of messenger RNAs encoding enkephalin, sub-
stance P, somatostatin, galanin, vasoactive intestinal polypeptide, neuropeptide Y,
and calcitonin gene-related peptide in the midbrain periaqueductal grey in the rat.
J Comp Neurol 350(1):23–40.
84. Kawa L, et al. (2016) Expression of galanin and its receptors are perturbed in a ro-
dent model of mild, blast-induced traumatic brain injury. Exp Neurol 279:159–167.
85. Wang P, et al. (2016) Depression-like behavior in rat: Involvement of galanin re-
ceptor subtype 1 in the ventral periaqueductal gray. Proc Natl Acad Sci USA 113(32):
E4726–35.
86. Drevets WC, Price JL, Furey ML (2008) Brain structural and functional abnormalities
in mood disorders: Implications for neurocircuitry models of depression. Brain Struct
Funct 213(1-2):93–118.
87. Pizzagalli DA (2011) Frontocingulate dysfunction in depression: Toward biomarkers
of treatment response. Neuropsychopharmacol 36(1):183–206.
88. Smith KE, et al. (1998) Cloned human and rat galanin GALR3 receptors. Pharma-
cology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem
273(36):23321–23326.
89. Jones EG (1986) Neurotransmitters in the cerebral cortex. J Neurosurg 65(2):135–153.
90. Savasta M, Palacios JM, Mengod G (1988) Regional localization of the mRNA coding
for the neuropeptide cholecystokinin in the rat brain studied by in situ hybridiza-
tion. Neurosci Lett 93(2-3):132–138.
91. Morino P, et al. (1994) Cholecystokinin in cortico-striatal neurons in the rat: Immu-
nohistochemical studies at the light and electron microscopical level. Eur J Neurosci
6(5):681–692.
92. Hedlund PB, Yanaihara N, Fuxe K (1992) Evidence for specific N-terminal galanin
fragment binding sites in the rat brain. Eur J Pharmacol 224(2-3):203–205.
93. Xu ZQ, Ma X, Soomets U, Langel U, Hökfelt T (1999) Electrophysiological evidence
for a hyperpolarizing, galanin (1-15)-selective receptor on hippocampal CA3 pyra-
midal neurons. Proc Natl Acad Sci USA 96(25):14583–14587.
94. Millón C, et al. (2016) Galanin (1-15) enhances the antidepressant effects of the
5-HT1A receptor agonist 8-OH-DPAT: Involvement of the raphe-hippocampal 5-HT
neuron system. Brain Struct Funct 221(9):4491–4504.
95. Peter CJ, Akbarian S (2011) Balancing histone methylation activities in psychiatric
disorders. Trends Mol Med 17(7):372–379.
96. Renthal W, Nestler EJ (2009) Chromatin regulation in drug addiction and depression.
Dialogues Clin Neurosci 11(3):257–268.
97. Lolak S, Suwannarat P, Lipsky RH (2014) Epigenetics of depression. Prog Mol Biol
Transl Sci 128:103–137.
98. Korf J, Aghajanian GK, Roth RH (1973) Increased turnover of norepinephrine in the
rat cerebral cortex during stress: Role of the locus coeruleus. Neuropharmacology
12(10):933–938.
99. Zigmond RE, Schon F, Iversen LL (1974) Increased tyrosine hydroxylase activity in the
locus coeruleus of rat brain stem after reserpine treatment and cold stress. Brain Res
70(3):547–552.
100. Svensson TH (1987) Stress, central neurotransmitters, and the mechanism of action
of alpha 2-adrenoceptor agonists. J Cardiovasc Pharmacol 10(Suppl 12):S88–S92.
101. Holmes PV, Blanchard DC, Blanchard RJ, Brady LS, Crawley JN (1995) Chronic social
stress increases levels of preprogalanin mRNA in the rat locus coeruleus. Pharmacol
Biochem Behav 50(4):655–660.
102. Sweerts BW, Jarrott B, Lawrence AJ (1999) Expression of preprogalanin mRNA fol-
lowing acute and chronic restraint stress in brains of normotensive and hypertensive
rats. Brain Res Mol Brain Res 69(1):113–123.
103. Andersson PO, Bloom SR, Edwards AV, Järhult J (1982) Effects of stimulation of the
chorda tympani in bursts on submaxillary responses in the cat. J Physiol 322:469–483.
104. Lundberg JM, Anggård A, Fahrenkrug J, Hökfelt T, Mutt V (1980) Vasoactive in-
testinal polypeptide in cholinergic neurons of exocrine glands: Functional signifi-
cance of coexisting transmitters for vasodilation and secretion. Proc Natl Acad Sci
USA 77(3):1651–1655.
105. Bean AJ, Roth RH (1991) Extracellular dopamine and neurotensin in rat prefrontal
cortex in vivo: Effects of median forebrain bundle stimulation frequency, stimula-
tion pattern, and dopamine autoreceptors. J Neurosci 11(9):2694–2702.
106. Consolo S, et al. (1994) Impulse flow dependency of galanin release in vivo in the rat
ventral hippocampus. Proc Natl Acad Sci USA 91(17):8047–8051.
107. Ludwig M, Leng G (2006) Dendritic peptide release and peptide-dependent be-
haviours. Nat Rev Neurosci 7(2):126–136.
108. Vila-Porcile E, et al. (2009) Dendritic synthesis and release of the neuropeptide
galanin: Morphological evidence from studies on rat locus coeruleus neurons.
J Comp Neurol 516(3):199–212.
109. Ma X, et al. (2001) Effects of galanin receptor agonists on locus coeruleus neurons.
Brain Res 919(1):169–174.
110. Wang S, Hashemi T, Fried S, Clemmons AL, Hawes BE (1998) Differential intracellular
signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 37(19):
6711–6717.
111. Steiner RA, et al. (2001) Galanin transgenic mice display cognitive and neurochem-
ical deficits characteristic of Alzheimer’s disease. Proc Natl Acad Sci USA 98(7):
4184–4189.
112. Holmes A, Yang RJ, Crawley JN (2002) Evaluation of an anxiety-related phenotype in
galanin overexpressing transgenic mice. J Mol Neurosci 18(1-2):151–165.
113. Hökfelt T (1991) Neuropeptides in perspective: The last ten years. Neuron 7(6):
867–879.
114. Plotsky PM, Owens MJ, Nemeroff CB (1995) Neuropeptide alterations in mood dis-
orders. Psychopharmacology: The Fourth Generation of Progress, ed Bloom FE (Ra-
ven, New York), 4th, pp 971–981.
115. Kramer MS, et al. (1998) Distinct mechanism for antidepressant activity by blockade
of central substance P receptors. Science 281(5383):1640–1645.
116. Ranga K, Krishnan R (2002) Clinical experience with substance P receptor (NK1)
antagonists in depression. J Clin Psychiatry 63(Suppl 11):25–29.
117. Frick A, et al. (2015) Increased neurokinin-1 receptor availability in the amygdala in
social anxiety disorder: A positron emission tomography study with [11C]GR205171.
Transl Psychiatry 5:e597.
118. Ratti E, et al. (2013) Full central neurokinin-1 receptor blockade is required for ef-
ficacy in depression: Evidence from orvepitant clinical studies. J Psychopharmacol
27(5):424–434.
119. Barr AM, et al. (2006) A novel, systemically active, selective galanin receptor type-3
ligand exhibits antidepressant-like activity in preclinical tests. Neurosci Lett 405(1-2):
111–115.
120. Swanson CJ, et al. (2005) Anxiolytic- and antidepressant-like profiles of the galanin-3
receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA
102(48):17489–17494.
121. Petschner P, et al. (2016) Chronic venlafaxine treatment fails to alter the levels of
galanin system transcripts in normal rats. Neuropeptides 57:65–70.
122. Asberg M, Thorén P, Träskman L, Bertilsson L, Ringberger V (1976) “Serotonin de-
pression”–a biochemical subgroup within the affective disorders? Science 191(4226):
478–480.
123. Palomero-Gallagher N, Mohlberg H, Zilles K, Vogt B (2008) Cytology and receptor
architecture of human anterior cingulate cortex. J Comp Neurol 508(6):906–926.
124. Foote SL, Bloom FE, Aston-Jones G (1983) Nucleus locus ceruleus: New evidence of
anatomical and physiological specificity. Physiol Rev 63(3):844–914.
125. Zhu PC, Thureson-Klein A, Klein RL (1986) Exocytosis from large dense cored vesicles
outside the active synaptic zones of terminals within the trigeminal subnucleus
caudalis: A possible mechanism for neuropeptide release. Neuroscience 19(1):43–54.
126. Dumais A, et al. (2005) Risk factors for suicide completion in major depression: A
case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry
162(11):2116–2124.
127. Paxinos G, Huang X-F (1995) Atlas of the Human Brainstem (Academic, San Diego).
128. Fleige S, Pfaffl MW (2006) RNA integrity and the effect on the real-time qRT-PCR
performance. Mol Aspects Med 27(2-3):126–139.
129. Tost J, Gut IG (2007) DNA methylation analysis by pyrosequencing. Nat Protoc 2(9):
2265–2275.
130. Unschuld PG, et al. (2008) Polymorphisms in the galanin gene are associated with
symptom-severity in female patients suffering from panic disorder. J Affect Disord
105(1-3):177–184.
131. Lesch KP, et al. (1996) Association of anxiety-related traits with a polymorphism in
the serotonin transporter gene regulatory region. Science 274(5292):1527–1531.
132. Canli T, Lesch KP (2007) Long story short: The serotonin transporter in emotion
regulation and social cognition. Nat Neurosci 10(9):1103–1109.
133. Misawa K, et al. (2016) Epigenetic inactivation of galanin and GALR1/2 is associated
with early recurrence in head and neck cancer. Clin Exp Metastasis 33(2):187–195.
134. Misawa Y, et al. (2014) Tumor suppressor activity and inactivation of galanin re-
ceptor type 2 by aberrant promoter methylation in head and neck cancer. Cancer
120(2):205–213.
135. Kohno D, et al. (2014) Dnmt3a in Sim1 neurons is necessary for normal energy ho-
meostasis. J Neurosci 34(46):15288–15296.
136. Ernst C, et al. (2008) The effects of pH on DNA methylation state: In vitro and post-
mortem brain studies. J Neurosci Methods 174(1):123–125.
137. Nagy C, et al. (2015) Effects of postmortem interval on biomolecule integrity in the
brain. J Neuropathol Exp Neurol 74(5):459–469.
138. Millon C, et al. (2015) A role for galanin N-terminal fragment (1-15) in anxiety- and
depression-related behaviors in rats. Int J Neuropsychopharmacol 18(3):1–13.
139. Liu Z, Xu Y, Wu L, Zhang S (2010) Evolution of galanin receptor genes: Insights from
the deuterostome genomes. J Biomol Struct Dyn 28(1):97–106.
140. Lang R, et al. (2005) Pharmacological and functional characterization of galanin-like
peptide fragments as potent galanin receptor agonists. Neuropeptides 39(3):
179–184.
141. Lu X, Lundström L, Bartfai T (2005b) Galanin (2-11) binds to GalR3 in transfected
cell lines: Limitations for pharmacological definition of receptor subtypes.
Neuropeptides 39(3):165–167.
142. Robinson J, et al. (2013) Development of a high-throughput screening-compatible
cell-based functional assay to identify small molecule probes of the galanin 3 re-
ceptor (GalR3). Assay Drug Dev Technol 11(8):468–477.
143. Lu X, Bartfai T (2009) Analyzing the validity of GalR1 and GalR2 antibodies using
knockout mice. Naunyn Schmiedebergs Arch Pharmacol 379(4):417–420.
144. Villar MJ, et al. (1989) Neuropeptide expression in rat dorsal root ganglion cells and
spinal cord after peripheral nerve injury with special reference to galanin.
Neuroscience 33(3):587–604.
Barde et al. PNAS | Published online December 9, 2016 | E8481
N
EU
RO
SC
IE
N
CE
PN
A
S
PL
U
S
